NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling

Antioxidants and Redox Signaling

Volumn 4, Issue 6, 2002, Pages 899-914

  Hanna, Ibrahim R ^a   Taniyama, Yoshihiro ^a   Szöcs, Katalin ^a   Rocic, Petra ^a   Griendling, Kathy K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTISENSE OLIGONUCLEOTIDE; CAPTOPRIL; CILAZAPRIL; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STAT1 PROTEIN; STAT2 PROTEIN; THROMBIN RECEPTOR; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; XANTHINE OXIDASE;

ANGIOPLASTY; ATHEROSCLEROSIS; DRUG EFFECT; ENDOTHELIUM LESION; ENZYME ACTIVATION; ENZYME STRUCTURE; HEART HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY DISEASE; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; REVIEW; VASCULAR SMOOTH MUSCLE;

JANUS;

EID: 0036936265     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/152308602762197443     Document Type: Review

References (162)

1. Amin JK, Xiao L, Pimental DR, Pagano PJ, Singh K, Sawyer DB, and Colucci WS. Reactive oxygen species mediate alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 33: 131-139, 2001.
2. 2 sensing is preserved in mice lacking the gp91phox subunit of NADPH oxidase. Proc Natl Acad Sci U S A 96: 7944-7949, 1999.
3. Azevedo LC, Pedro MA, Souza LC, de Souza HP, Janiszewski M, da Luz PL, and Laurindo FR. Oxidative stress as a signaling mechanism of the vascular response to injury. The redox hypothesis of restenosis. Cardiovasc Res 47: 436-445, 2000.
4. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, and Yokoyama M. Expression of NADH/NADPH oxidase p22(phox) in human coronary arteries. Circulation 100: 1494-1498, 1999.
5. Babior BM. NADPH oxidase: An update. Blood 93: 1464-1476, 1999.
6. 2 production requires the activation of phosphatidylinositol 3-kinase. J Biol Chem 275: 10527-10531, 2000.
7. + channel generated through alternative splicing of the NADPH oxidase homolog NOH-1. Science 287: 138-142, 2000.
8. Barchowsky A, Munro SR, Morana SJ, Vincenti MP, and Treadwell M. Oxidant-sensitive and phosphorylation-dependent activation of NF-κB and AP-1 in endothelial cells. Am J Physiol 269: L829-L836, 1995.
9. Bardy N, Merval R, Benessiano J, Samuel JL, and Tedgui A. Pressure and angiotensin II synergistically induce aortic fibronectin expression in organ culture model of rabbit aorta. Evidence for a pressure-induced tissue renin-angiotensin system. Circ Res 79: 70-78, 1996.
10. Barry-Lane PA, Patterson C, van der Merwe M, Hu Z, Holland SM, Yeh ET, and Runge MS. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J Clin Invest 108: 1513-1522, 2001.
11. Bayraktutan U, Draper N, Lang D, and Shah AM. Expression of functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells. Cardiovasc Res 38:256-262, 1998.
12. Bayraktutan U, Blayney L, and Shah AM. Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscler Thromb Vasc Biol 20: 1903-1911, 2000.
13. Bech-Laursen J, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, and Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95: 588-593, 1997.
14. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, and Dominiczak AF. Investigation into the sources of superoxide in human blood vessels: Angiotensin II increases superoxide production in human internal mammary arteries. Circulation 101: 2206-2212, 2000.
15. Brandes RP, Viedt C, Nguyen K, Beer S, Kreuzer J, Busse R, and Gorlach A. Thrombin-induced MCP-1 expression involves activation of the p22phox-containing NADPH oxidase in human vascular smooth muscle cells. Thromb Haemost 85: 1104-1110, 2001.
16. Capers Q, Alexander RW, Lou P, De Leon H, Wilcox JN, Ishizaka N, Howard AB, and Taylor WR. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 30: 1397-1402, 1997.
17. Capers Q, Laursen JB, Fukui T, Rajagopalan S, Mori I, Lou P, Freeman BA, Berrington WR, Griendling KK, Harrison DG, Runge MS, Alexander RW, and Taylor WR. Vascular thrombin receptor regulation in hypertensive rats. Circ Res 80: 838-844, 1997.
18. Chen XL, Tummala PE, Olbrych MT, Alexander RW, and Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 83: 952-959, 1998.
19. Cheng G, Cao Z, Xu X, van Meir EG, and Lambeth JD. Homologs of gp91 phox: Cloning and tissue expression of Nox3, Nox4, and Nox5. Gene 269: 131-140, 2001.
20. Chobanian AV, Haudenschild CC, Nickerson C, and Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 15: 327-331, 1990.
21. Cifuentes ME, Rey FE, Carretero OA, and Pagano PJ. Upregulation of p67(phox) and gp91(phox) in aortas from angiotensin II-infused mice. Am J Physiol Heart Circ Physiol 279: H2234-H2240, 2000.
22. Cross AR. p40(phox) participates in the activation of NADPH oxidase by increasing the affinity of p47(phox) for flavocytochrome b(558). Biochem J 349: 113-117, 2000.
23. Dahan I, Issaeva I, Gorzalczany Y, Sigal N, Hirshberg M, and Pick E. Mapping of functional domains in the p22(phox) subunit of flavocytochrome b(559) participating in the assembly of the NADPH oxidase complex by "peptide walking." J Biol Chem 277: 8421-8432, 2002.
24. Daugherty A, Manning MW, and Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105: 1605-1612, 2000.
25. DeLeo FR, Burritt JB, Yu L, Jesaitis AJ, Dinauer MC, and Nauseef WM. Processing and maturation of flavocytochrome b558 include incorporation of heme as a prerequisite for heterodimer assembly. J Biol Chem 275: 13986-13993, 2000.
26. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, and Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94: 2756-2767, 1996.
27. Dijkhorst-Oei LT, Stroes ES, Koomans HA, and Rabelink TJ. Acute simultaneous stimulation of nitric oxide and oxygen radicals by angiotensin II in humans in vivo. J Cardiovasc Pharmacol 33: 420-424, 1999.
28. Dobrian AD, Schriver SD, and Prewitt RL. Role of angiotensin II and free radicals in blood pressure regulation in a rat model of renal hypertension. Hypertension 38: 361-366, 2001.
29. 2+-depleted neutrophils. Biochem J 290: 173-178, 1993.
30. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 25: 362-369, 1995
31. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, Brandes RP, and Busse R. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88: 44-51, 2001.
32. Fogo AB. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 35: 179-188, 2000.
33. Frank GD, Motley ED, Inagami T, and Eguchi S. PYK2/CAKbeta represents a redox-sensitive tyrosine kinase in vascular smooth muscle cells. Biochem Biophys Res Commun 270: 761-765, 2000.
34. Frank GD, Eguchi S, Inagami T, and Motley ED. N-acetylcysteine inhibits angiotensin II-mediated activation of extracellular signal-regulated kinase and epidermal growth factor receptor. Biochem Biophys Res Commun 280: 1116-1119, 2001.
35. Freyschuss A, Stiko-Rahm A, Swedenborg J, Henriksson P, Bjorkhem I, Berglund L, and Nilsson J. Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J Clin Invest 91: 1282-1288, 1993.
36. 558 α-subunit in rat vascular smooth muscle cells. Biochim Biophys Acta 1231: 215-219, 1995.
37. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q 4th, Taylor WR, Harrison DG, de Leon H, Wilcox JN, and Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45-51, 1997.
38. Geiszt M, Kopp JB, Varnai P, and Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A 97: 8010-8014, 2000.
39. Goetz RM and Holtz J. Angiotensin-converting enzyme: Induction by hypertension-induced vessel distention. Blood Press 9: 40-46, 2000.
40. Gong KW, Zhu GY, Wang LH, and Tang CS. Effect of active oxygen species on intimal proliferation in rat aorta after arterial injury. J Vasc Res 33: 42-46, 1996.
41. Gorin Y, Kim NH, Feliers D, Bhandari B, Choudhury GG, and Abboud HE. Angiotensin II activates Akt/protein kinase B by an arachidonic acid/redox-dependent pathway and independent of phosphoinositide 3-kinase. FASEB J 15: 1909-1920, 2001.
42. Görlach A, Brandes RP, Bassus S, Kronemann N, Kirchmaier CM, Busse R, and Schini-Kerth VB. Oxidative stress and expression of p22phox are involved in the up-regulation of tissue factor in vascular smooth muscle cells in response to activated platelets. FASEB J 14: 1518-1528, 2000.
43. Görlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, and Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 87: 26-32, 2000.
44. Görlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, Kietzmann T, and Busse R. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase. Circ Res 89: 47-54, 2001.
45. Govindarajan G, Eble DM, Lucchesi PA, and Samarel AM. Focal adhesion kinase is involved in angiotensin II-mediated protein synthesis in cultured vascular smooth muscle cells. Circ Res 87: 710-716, 2000.
46. Griendling KK and Ushio-Fukai M. Redox control of vascular smooth muscle proliferation. J Lab Clin Med 132: 9-15, 1998.
47. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
48. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, and Channon KM. Vascular superoxide production by NAD(P)H oxidase: Association with endothelial dysfunction and clinical risk factors. Circ Res 86: E85-E90, 2000.
49. Hannken T, Schroeder R, Stahl RA, and Wolf G. Angiotensin II-mediated expression of p27Kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int 54: 1923-1933, 1998.
50. Hannken T, Schroeder R, Zahner G, Stahl RA, and Wolf G. Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27(Kip1): Role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol 11: 1387-1397, 2000.
51. Hanson SR, Powell JS, Dodson T, Lumsden A, Kelly AB, Anderson JS, Clowes AW, and Harker LA. Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon. Hypertension 18 (Suppl II): II-70-II-76, 1991.
52. Harada K, Komuro I, Sugaya T, Murakami K, and Yazaki Y. Vascular injury causes neointimal formation in angiotensin II type Ia receptor knockout mice. Circ Res 84: 179-185, 1999.
53. Haugen EN, Croatt AJ, and Nath KA. Angiotensin II induces renal oxidant stress in vivo and heme oxygenase-1 in vivo and in vitro. Kidney Int 58: 144-152, 2000.
54. Holland JA, Pritchard KA, Pappolla MA, Wolin MS, Rogers NJ, and Stemerman MB. Bradykinin induces superoxide anion release from human endothelial cells. J Cell Physiol 143: 21-25, 1990.
55. Holland JA, Meyer JW, Chang MM, O'Donnell RW, Johnson DK, and Ziegler LM. Thrombin stimulated reactive oxygen species production in cultured human endothelial cells. Endothelium 6: 113-121, 1998.
56. Howard AB, Alexander RW, Nerem RM, Griendling KK, and Taylor WR. Cyclic strain induces an oxidative stress in endothelial cells. Am J Physiol 272: C421-C427, 1997.
57. Hsu TC, Young MR, Cmarik J, and Colburn NH. Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 28: 1338-1348, 2000.
58. Huckle WR, Drag MD, Acker WR, Powers M, McFall RC, Holder DJ, Fujita T, Stabilito II, Kim D, Ondeyka DL, Mantlo NB, Chang RS, Reilly CF, Schwartz RS, Greenlee WJ, and Johnson RG Jr. Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis. Circulation 93: 1009-1019, 1996.
59. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Arimura K, Egashira K, and Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 85: 357-363, 1999.
60. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, and Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in rastransformed fibroblasts. Science 275: 1649-1652, 1997.
61. Jones SA, O'Donnell VB, Wood JD, Broughton JP, Hughes EJ, and Jones OTG. Expression of phagocyte NADPH oxidase components in human endothelial cells. Am J Physiol 271: H1626-H1634, 1996.
62. Kauffman RF, Bean JS, Zimmerman KM, Brown RF, and Steinberg MI. Losartan, a nonpeptide angiotensin II (Ang II) receptor antagonist, inhibits neointima formation following balloon injury to rat carotid arteries. Life Sci 49: L223-L228, 1991.
63. Kim S and Iwao H. Involvement of angiotensin II in cardiovascular and renal injury: Effects of an AT1-receptor antagonist on gene expression and the cellular phenotype. J Hypertens Suppl 15: S3-S7, 1997.
64. Kinnula VL, Mirza Z, Crapo JD, and Whorton AR. Modulation of hydrogen peroxide release from vascular endothelial cells by oxygen. Am J Respir Cell Mol Biol 9: 603-609, 1993.
65. Klahr S. Oxygen radicals and renal diseases. Miner Electrolyte Metab 23: 140-143, 1997.
66. Laragh JH and Sealy JE. The renin-angiotensin-aldosterone system in hypertensive disorders: A key to two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis. In: Hypertension: Pathophysiology, Diagnosis, and Management, edited by Laragh JH and Brenner BM. New York: Raven Press, 1990, pp. 1329-1348.
67. Lassègue B, Sorescu D, Szöcs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, and Griendling KK. Novel gp91phox homologues in vascular smooth muscle cells: Nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88: 888-894, 2001.
68. Lavigne MC, Malech HL, Holland SM, and Leto TL. Genetic demonstration of p47phox-dependent superoxide anion production in murine vascular smooth muscle cells. Circulation 104: 79-84, 2001.
69. Leehey DJ, Singh AK, Alavi N, and Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 77: S93-S98, 2000.
70. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C, and Romero JC. Increased oxidative stress in experimental renovascular hypertension. Hypertension 37: 541-546, 2001.
71. Leusen JH, Verhoeven AJ, and Roos D. Interactions between the components of the human NADPH oxidase: Intrigues in the phox family. J Lab Clin Med 128: 461-476, 1996.
72. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Luscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, and Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 94: 258-265, 1996.
73. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, and Bernstein KE. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375: 247-250, 1995.
74. Marui N, Offerman M, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, and Medford RM. Vascular cell-adhesion molecule-1 (VCAM-1) gene-transcription and expression are regulated through an antioxidant sensitive mechanism in human vascular endothelial cells. J Clin Invest 92: 1866-1874, 1993.
75. McWhinney CD, Dostal D, and Baker K. Angiotensin II activates Stat5 through Jak2 kinase in cardiac myocytes. J Mol Cell Cardiol 30: 751-761, 1998.
76. Meier B. Regulation of the superoxide releasing system in human fibroblasts. Adv Exp Med Biol 387: 113-116, 1996.
77. Mercator Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multi-center European Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation 86:100-110, 1992.
78. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, and Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res 82: 1298-1305, 1998.
79. Mohazzab KM and Wolin MS. Sites of superoxide anion production detected by lucigenin in calf pulmonary artery smooth muscle. Am J Physiol 267: L815-L822, 1994.
80. Mohazzab KM, Kaminski PM, and Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 266: H2568-H2572, 1994.
81. Morishita R, Gibbons GH, Tomita N, Zhang L, Kaneda Y, Ogihara T, and Dzau VJ. Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: Evidence for tissue angiotensin-converting enzyme function. Arterioscler Thromb Vasc Biol 20: 915-922, 2000.
82. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, and Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 98: 794-799, 1998.
83. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, and Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci U S A 88: 10045-10048, 1991.
84. Nath KA and Norby SM. Reactive oxygen species and acute renal failure. Am J Med 109: 665-678, 2000.
85. Nishiyama A, Fukui T, Fujisawa Y, Rahman M, Tian RX, Kimura S, and Abe Y. Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats. Hypertension 37: 77-83, 2001.
86. Nozawa Y, Matsuura N, Miyake H, Yamada S, and Kimura R. Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury. Life Sci 64: 2061-2070, 1999.
87. − production in the pig coronary artery. Circulation 96: 3593-3601, 1997.
88. Osterrieder W, Muller RK, Powell JS, Clozel JP, Hefti F, and Baumgartner HR. Role of angiotensin II in injury-induced neointima formation in rats. Hypertension 18: II60-II64, 1991.
89. Packer M. Beta-blockade in heart failure. Basic concepts and clinical results. Am J Hypertens 11: 23S-37S, 1998.
90. Pagano PJ, Tornheim K, and Cohen RA. Superoxide anion production by rabbit thoracic aorta: Effect of endothelium-derived nitric oxide. Am J Physiol 265: H707-H712, 1993.
91. Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark SM, Callis GM, and Quinn MT. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: Enhancement by angiotensin II. Proc Natl Acad Sci U S A 94: 14438-14488, 1997.
92. Pagano PJ, Chanock SJ, Siwik DA, Colucci WS, and Clark JK. Angiotensin II induces p67phox mRNA expression and NADPH oxidase superoxide generation in rabbit aortic adventitial fibroblasts. Hypertension 32: 331-337, 1998.
93. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, Ballinger CA, Brasier AR, Bode C, and Runge MS. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem 274: 19814-19822, 1999.
94. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327: 669-677, 1992.
95. Phan SH, Gannon DE, Varani J, Ryan US, and Ward PA. Xanthine oxidase activity in rat pulmonary artery endothelial cells and its alteration by activated neutrophils. Am J Pathol 134: 1201-1211, 1989.
96. Pollman MJ, Hall JL, and Gibbons GH. Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury. Influence of redox state and cell phenotype. Circ Res 84: 113-121, 1999.
97. Potter DD, Sobey CG, Tompkins PK, Rossen JD, and Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 98: 800-807, 1998.
98. Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, and Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245: 186-188, 1989.
99. Pratt RE and Dzau VJ. Pharmacological strategies to prevent restenosis: Lessons learned from blockade of the renin-angiotensin system [Editorial]. Circulation 93: 848-852, 1996.
100. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, and Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 20: 645-651, 2000.
101. Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, and Levrero M. Reactive oxygen intermediates mediate angiotensin II-induced c-Jun. c-Fos heterodimer DNA binding activity and proliferative hypertrophic responses in myogenic cells. J Biol Chem 270: 22129-22134, 1995.
102. 558 and 45-kDa flavoprotein) by intrinsic human glomerular mesangial cells. J Biol Chem 266: 21025-21029, 1991.
103. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, and Harrison DG. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923, 1996.
104. Rao GN, Alexander RW, and Runge MS. Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-Fos, c-Jun, and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest 96: 842-847, 1995.
105. Ratych RE, Chuknyiska RS, and Bulkley GB. The primary localization of free radical generation after anoxia/reoxygenation in isolated endothelial cells. Surgery 102: 122-131, 1987.
106. Regier DS, Greene DG, Sergeant S, Jesaitis AJ, and McPhail LC. Phosphorylation of p22phox is mediated by phospholipase D-dependent and -independent mechanisms. Correlation of NADPH oxidase activity and p22phox phosphorylation. J Biol Chem 275: 28406-28412, 2000.
107. Rocic P and Lucchesi PA. Down-regulation by antisense oligonucleotides establishes a role for the proline-rich tyrosine kinase PYK2 in angiotensin ii-induced signaling in vascular smooth muscle. J Biol Chem 276: 21902-21906, 2001.
108. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, and Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 10: 321-329, 2001.
109. Russo C, Olivieri O, Girelli D, Faccini G, Zenari ML, Lombardi S, and Corrocher R. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J Hypertens 16: 1267-1271, 1998.
110. Sabri A, Govindarajan G, Griffin TM, Byron KL, Samarel AM, and Lucchesi PA. Calcium- and protein kinase C-dependent activation of the tyrosine kinase PYK2 by angiotensin II in vascular smooth muscle. Circ Res 83: 841-851, 1998.
111. Sadoshima J and Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 73: 413-423, 1993.
112. Sagar S, Kallo IJ, Kaul N, Ganguly NK, and Sharma BK. Oxygen free radicals in essential hypertension. Mol Cell Biochem 111: 103-108, 1992.
113. Salahudeen AK, Kanji V, Reckelhoff JF, and Schmidt AM. Pathogenesis of diabetic nephropathy: A radical approach. Nephrol Dial Transplant 12: 664-668, 1997.
114. Sano M, Fukuda K, Sato T, Kawaguchi H, Suematsu M, Matsuda S, Koyasu S, Matsui H, Yamauchi-Takihara K, Harada M, Saito Y, and Ogawa S. ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ Res 89: 661-669, 2001.
115. Schaller MD and Parsons JT. Focal adhesion kinase: An integrin linked protein tyrosine kinase. Trends Cell Biol 3: 258-261, 1993.
116. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, and Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 87: 1195-1201, 2000.
117. Schnackenberg CG and Wilcox CS. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension 33:424-428, 1999.
118. Schnackenberg CG, Welch WJ, and Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: Role of nitric oxide. Hypertension 32: 59-64, 1998.
119. Schwartz SM, Majesky MW, and Dilley RJ. Vascular remodeling in hypertension and atherosclerosis. In: Hypertension: Pathophysiology, Diagnosis and Management, edited by Laragh JH and Brenner BM. New York: Raven Press, 1990, pp. 521-539.
120. Scott NA, Cipolla GD, Ross CE, Dunn B, Martin FH, Simonet L, and Wilcox JN. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 93: 2178-2187, 1996.
121. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, and Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: Upstream mediators. Circ Res 91: 406-413, 2002.
122. Shi Y, Niculescu R, Wang D, Patel S, Davenpeck KL, and Zalewski A. Increased NAD(P)H oxidase and reactive oxygen species in coronary arteries after balloon injury. Arterioscler Thromb Vasc Biol 21: 739-745, 2001.
123. Shiose A, Kuroda J, Tsuruya K, Hirai M, Hirakata H, Naito S, Hattori M, Sakaki Y, and Sumimoto H. A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 276: 1417-1423, 2001.
124. Siwik DA, Tzortzis JD, Pimental DR, Chang DL, Pagano PJ, Singh K, Sawyer DB, and Colucci WS. Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. Circ Res 85: 147-153, 1999.
125. Somers MJ, Mavromatis K, Galis ZS, and Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 101: 1722-1728, 2000.
126. Sorescu D, Weiss D, Lassègue B, Szöcs K, Vega JD, Taylor WR, and Griendling KK. Expression of the NAD(P)H oxidase subunits in human coronary arteries. Circulation 104: II-41, 2001.
127. Souren JE, Van Der Mast C, and Van Wijk R. NADPH-oxidase-dependent superoxide production by myocyte-derived H9c2 cells: Influence of ischemia, heat shock, cycloheximide and cytochalasin D. J Mol Cell Cardiol 29: 2803-2812, 1997.
128. Souza HP, Souza LC, Anastacio VM, Pereira AC, Junqueira ML, Krieger JE, da Luz PL, Augusto O, and Laurindo FR. Vascular oxidant stress early after balloon injury: Evidence for increased NAD(P)H oxidoreductase activity. Free Radic Biol Med 28: 1232-1242, 2000.
129. Souza HP, Laurindo FRM, Ziegelstein RC, Berlowitz CO, and Zweier JL. Vascular NAD(P)H oxidase is distinct from the phagocytic enzyme and modulates vascular reactivity control. Am J Physiol Heart Circ Physiol 280: H658-H667, 2001.
130. Spiecker M, Darius H, Kaboth K, Hübner F, and Liao JK. Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J Leukoc Biol 63: 732-739, 1998.
131. Suh Y, Arnold RS, Lassègue B, Shi J, Xu X, Sorescu D, Chung AB, Griendling KK, and Lambeth JD. Cell transformation by the superoxide-generating oxidase mox1. Nature 401: 79-82, 1999.
132. 2 for platelet-derived growth factor signal transduction. Science 270: 296-299, 1995.
133. Suzuki H, Swei A, Zweifach BW, and Schmid-Schonbein GW. In vivo evidence for microvascular oxidative stress in spontaneously hypertensive rats. Hydroethidine micro-fluorography. Hypertension 25: 1083-1089, 1995.
134. Swei A, Lacy F, DeLano FA, and Schmid-Schonbein GW. Oxidative stress in the Dah1 hypertensive rat. Hypertension 30: 1628-1633, 1997.
135. Szöcs K, Lassègue B, Sorescu D, Hilenski LL, Valppu L, Couse TL, Wilcox JN, Quinn MT, Lambeth JD, and Griendling KK. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 22: 21-27, 2002.
136. Taal MW and Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 57: 1803-1817, 2000.
137. Tesfamariam B and Cohen RA. Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am J Physiol 262: H1915-H1919, 1992.
138. Touyz R, Chen X, He G, Quinn MT, and Schiffrin EL. Expression of a gp91phox-containing leukocyte-type NAD(P)H oxidase in smooth muscle cells from human small arteries-modulation by Ang II. Circulation 104: II-450, 2001.
139. Touyz RM and Schiffrin EL. Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension 34: 976-982, 1999.
140. Touyz RM and Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: Role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 19: 1245-1254, 2001.
141. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG, and Medford RM. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation 100: 1223-1229, 1999.
142. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, and Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271: 23317-23321, 1996.
143. Ushio-Fukai M, Alexander RW, Akers M, and Griendling KK. p38 mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II: Role in vascular smooth muscle cell hypertrophy. J Biol Chem 273: 15022-15029, 1998.
144. Ushio-Fukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, and Griendling KK. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 274: 22699-22704, 1999.
145. Ushio-Fukai M, Griendling KK, Becker PL, Hilenski L, Halleran S, and Alexander RW. Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 21: 489-495, 2001.
146. Viedt C, Soto U, Krieger-Brauer HI, Fei J, Elsing C, Kubler W, and Kreuzer J. Differential activation of mitogen-activated protein kinases in smooth muscle cells by angiotensin II: Involvement of p22phox and reactive oxygen species. Arterioscler Thromb Vasc Biol 20: 940-948, 2000.
147. Wallach TM and Segal AW. Stoichiometry of the subunits of flavocytochrome b558 of the NADPH oxidase of phagocytes. Biochem J 320: 33-38, 1996.
148. 2+ levels. J Biol Chem 275: 12223-12230, 2000.
149. Wang HD, Xu S, Johns DG, Du Y, Quinn MT, Cayatte AJ, and Cohen RA. Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 88: 947-953, 2001.
150. Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, and Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. Circulation 99: 2027-2033, 1999.
151. Weiss D, Kools JJ, and Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 103: 448-454, 2001.
152. Welch WJ and Wilcox CS. AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Kidney Int 59: 1257-1263, 2001.
153. Welch WJ, Tojo A, and Wilcox CS. Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR. Am J Physiol Renal Physiol 278: F769-F776, 2000.
154. Wilson DP, Saward L, Zahradka P, and Cheung PK. Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model. Cardiovasc Res 42: 761-772, 1999.
155. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, and Gilbert RE. Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system. Kidney Int 51: 1553-1567, 1997.
156. Xie Z, Pimental DR, Lohan S, Vasertriger A, Pligavko C, Colucci WS, and Singh K. Regulation of angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells: Role of p42/44 mitogen-activated protein kinase and reactive oxygen species. J Cell Physiol 188: 132-138, 2001.
157. Yeh LH, Park YJ, Hansalia RJ, Ahmed IS, Deshpande SS, Goldschmidt-Clermont PJ, Irani K, and Alevriadou BR. Shear-induced tyrosine phosphorylation in endothelial cells requires Rac1-dependent production of ROS. Am J Physiol 276: C838-C847, 1999.
158. Yu L, Zhen L, and Dinauer MC. Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits. J Biol Chem 272: 27288-27294, 1997.
159. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, and Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [see comments] [published errata appear in N Engl J Med 342: 748 and 1376, 2000]. N Engl J Med 342: 145-153, 2000.
160. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, Taylor WR, and Griendling KK. Novel role of NADH/NADPH oxidase-derived hydrogen peroxide in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension 32: 488-495, 1998.
161. Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A, and Daniel WG. Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 44: 215-222, 1999.
162. Zweier JL, Kuppusamy P, and Lutty GA. Measurement of endothelial cell free radical generation: Evidence for a central mechanism of free radical injury in postischemic tissues. Proc Natl Acad Sci U S A 85: 4046-4050, 1988.